(Albany, New York)- 2nd Sep 2026 – DelveInsight’s “HPV Testing and Pap Test Market” report delivers an in-depth understanding of the global HPV testing and Pap test market, covering market size, growth trends, segmentation, competitive landscape, and regional dynamics across North America, Europe, and Asia-Pacific.
Curious to know what’s driving the growth of the HPV testing and Pap test market through 2034?
Download the report to understand the latest HPV Testing and Pap Test market trends and forecasts- HPV Testing and Pap Test Market – https://www.delveinsight.com/report-store/hpv-testing-and-pap-test-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr
Key Takeaways from the HPV Testing and Pap Test Market Report
The global HPV testing and Pap test market is expected to increase from USD 3,702.30 million in 2025 to USD 6,524.39 million by 2034, growing at a CAGR of 6.56% from 2026 to 2034.
North America is expected to dominate the market, accounting for 40.5% of the global share in 2025, driven by high cervical cancer prevalence, strong screening awareness, and favorable reimbursement policies.
Asia-Pacific is projected to be the fastest-growing region, with a CAGR of around 9%, supported by rising disease burden, urbanization, and expanding national screening programs.
The Pap test category contributes 63% of total market revenue in the test type segment, while consumables dominate the product type segment with a 63% share in 2025.
The competitive landscape features companies including F. Hoffmann-La Roche, Hologic, QIAGEN, Abbott Laboratories, and Becton Dickinson, among others, competing on technological innovation, test accuracy, and high-throughput molecular diagnostics.
Gain a competitive edge in the HPV Testing and Pap Test Market by exploring our in-depth analysis @ HPV Testing and Pap Test Market
HPV Testing and Pap Test Market Overview
HPV testing and the Pap test (Pap smear) are screening methods used to detect early signs of cervical cancer. HPV testing identifies the presence of high-risk types of Human papillomavirus that can lead to cervical cancer, while the Pap test examines cervical cells to detect abnormal or precancerous changes. Together, they help in early detection and prevention by identifying either the underlying cause or the resulting cellular abnormalities. The rising prevalence of cervical cancer, primarily driven by HPV infection, is significantly increasing demand for these screening solutions, while continuous advancements in molecular diagnostic technologies, including PCR-based methods and mRNA-based assays, are enhancing sensitivity and specificity, enabling earlier and more reliable diagnosis compared to traditional cytology alone.
HPV Testing and Pap Test Market Dynamics and Trends
The rising burden of cervical cancer and HPV infections worldwide is a major growth driver. According to the International Agency for Research on Cancer (2025), an estimated 7,02,616 new cervical cancer cases occurred globally in 2025, projected to rise to 9,08,612 by 2045. Per WHO (2024) data, HPV caused an estimated 6,20,000 cancer cases in women and 70,000 in men in 2019.
Growing awareness and government-led screening programs, including WHO’s cervical cancer elimination strategy and national initiatives such as India’s NPCDCS, are expanding testing volumes and improving compliance, including through self-sampling HPV kits.
Increasing product development activity is also boosting the market; for instance, in February 2026 Hologic’s Aptima® HPV Assay received FDA approval for clinician-collected HPV primary screening as the only FDA-approved mRNA-based assay of its kind.
However, limited sensitivity and possible false results in Pap tests, along with patient discomfort during pelvic examinations, act as restraints, contributing to lower screening participation in populations with low HPV awareness.
HPV Testing and Pap Test Market Segment Analysis
By Test Type: The Pap test dominates with 63% of total revenue in 2025, owing to its affordability, long-standing clinical acceptance, and suitability for large-scale screening in low- and middle-income countries; liquid-based cytology advancements have further improved its diagnostic accuracy.
By Product Type: Consumables lead with around 63% share in 2025, driven by recurring demand for reagents, assay kits, collection media, and cytology slides across every screening cycle, reinforced by a razor-and-blade business model.
By Technology: Molecular diagnostics leads with around 43% share in 2025, owing to the high sensitivity of PCR and mRNA-based assays for detecting high-risk HPV infections.
By Application: Follow-up testing dominates, driven by the need for confirmatory diagnostics such as repeat cytology, HPV genotyping, colposcopy, or biopsy after abnormal primary screening results.
By End-Users: Hospitals dominate due to advanced diagnostic infrastructure, skilled professionals, and the ability to deliver comprehensive screening and follow-up care in one setting.
Discover key developments and opportunities in the HPV Testing and Pap Test Market @ HPV Testing and Pap Test Market
HPV Testing and Pap Test Market Regional Analysis
North America: Expected to hold the largest share (40.5% in 2025). The American Cancer Society (2026) projects about 13,490 new invasive cervical cancer cases and 4,200 deaths in the US in 2026. CDC data (2025) attributes 39,300 cancers annually (79%) to HPV during 2018–2022. Initiatives such as Cervical Cancer Awareness Month in Canada, updated 2025 American Cancer Society screening guidelines, and WHO’s World Cervical Cancer Elimination Day are boosting participation. In January 2026, Teal Health launched national availability of its FDA-authorized at-home Teal Wand™ self-collection device with a telehealth platform.
Europe: Growing steadily, with the HPV Information Centre (2023) estimating 58,169 new cervical cancer diagnoses and 25,989 deaths annually. Structured screening initiatives under Europe’s Beating Cancer Plan and a shift toward HPV-based primary screening, alongside HPV vaccination integration and emerging self-sampling options, are supporting market expansion.
Asia-Pacific: The fastest-growing region, at a CAGR of around 9%. The International Agency for Research on Cancer (2026) estimates 1,38,871 new cervical cancer cases in India in 2025, rising to 2,12,623 by 2045. Rapid urbanization, rising healthcare investment in China, India, and Southeast Asia, and government screening and awareness programs are driving growth, along with cost-effective diagnostic solutions.
Recent Developmental Activities in the HPV Testing and Pap Test Market
In February 2026, Hologic announced FDA approval of its Aptima® HPV Assay for clinician-collected HPV primary screening.
In January 2026, Teal Health announced national availability of its at-home cervical cancer screening with the FDA-authorized Teal Wand™ device.
In April 2025, Quest Diagnostics launched an FDA-cleared HPV self-collection service for high-risk HPV testing in clinical settings.
HPV Testing and Pap Test Key Companies
F. Hoffmann-La Roche
Hologic Inc.
Becton Dickinson
QIAGEN
Abbott Laboratories
Danaher Corporation
Siemens Healthineers
Seegene Inc.
Bio-Rad Laboratories
Thermo Fisher Scientific
Femasys Inc.
Arbor Vita Corporation
Quest Diagnostics
LabCorp
Sysmex Corporation
FUJIFILM Holdings
Olympus Corporation
CooperSurgical
Cardinal Health
Nihon Kohden
And Others.
Scope of the HPV Testing and Pap Test Market Report
Forecast Period: 2026–2034
Market Size (2025): USD 3,702.30 Million
Market Size (2034): USD 6,524.39 Million
Growth Rate: 6.56% CAGR (2026–2034)
Geographies Covered: North America, Europe, Asia-Pacific, and Rest of the World
Market Structure: Moderately Concentrated
Major HPV Testing and Pap Test Companies: F. Hoffmann-La Roche, Hologic, Becton Dickinson, QIAGEN, Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Seegene, Bio-Rad Laboratories, Thermo Fisher Scientific, and others.
Market Segments Covered: Test Type (HPV Testing, Pap Test), Product Type (Instruments, Consumables), Technology (Molecular Diagnostics, Cytology, Others), Application (Follow-up testing, Co-testing, Primary HPV), End-Users (Hospitals, Diagnostic Laboratories, Others).
Key Focus Areas: HPV Testing and Pap Test Market Dynamics, Segment Analysis, Regional Analysis, Competitive Landscape, and Recent Developmental Activities.
Table of Contents
Introduction
Executive Summary
Key Factors Analysis
Impact Analysis
Regulatory Analysis
Porter’s Five Forces Analysis
Market Assessment
Competitive Landscape
Startup Funding & Investment Trends
Company and Product Profiles
KOL Views
Project Approach
About DelveInsight
Disclaimer & Contact Us
Media ContactCompany Name: DelveInsight Business ResearchContact Person: Abhishek kumarEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/report-store/hpv-testing-and-pap-test-market
